San Mamés, Bilbao 相關
廣告San Mamés Hotel Bilbao. Rooms, Rates, Deals for 2023. Our expert guide to the best stays. We compare the best hotels with balconies, views, pools, restaurants & more.
The closest thing to an exhaustive search you can find - SMH
搜尋結果
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the results of an analysis of a Phase III trial (REFLECT study / Study 304)1 of its in-house discovered and developed anticancer agent lenvatinib mesylate (product names: Lenvima® / Kisplyx®, “lenvatinib”) versus sorafenib as first-line treatment for unresectab...
2018年1月22日 · Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the results of an analysis of a Phase Ⅲ trial (REFLECT study / Study 304) 1 of its in-house discovered and developed anticancer agent lenvatinib mesylate (product names: Lenvima® / Kisplyx®, “lenvatinib”) versus sorafenib as first-line treatment for unresectabl...
2019年1月15日 · Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that presentations on a series of abstracts highlighting the latest data from post-hoc analyses of a Phase III clinical study (REFLECT/Study 304) on its in-house discovered ®
2015年7月31日 · TOKYO and San Diego, CA – July 31, 2014 – Eisai Co., Ltd. and Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that they have signed a clinical collaboration agreement to evaluate Eisai's anticancer agent eribulin mesylate (brand name: Halaven®, “eribulin”) in combination with Halozyme's investigational new drug ...
Representative Director, President and Chief Executive Officer (CEO) of the Company. Jun. 2004. Director, President (Representative Corporate Officer) and CEO of the Company. Jan. 2006. Chair, The Naito Foundation (current) Jun. 2014. Director, Representative Corporate Officer and CEO of the Company (current) Back to the Corporate Executives List.
2023年8月25日 · Our efforts on global health started in early 2000s. By creating novel medicines for global health, our mission is to relieve anxiety over health and reduce health disparities in disease endemic countries and thus efficiently achieve social good.
2023年12月9日 · Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-001 Trial Evaluating LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma.
